Boehringer Ingelheim’s obesity shot, survodutide (licensed from Zealand Pharma), saw notable Phase 3 discontinuations attributed to side effects, according to SYNCHRONIZE-1 reporting referenced in ADA26 coverage. The update adds to scrutiny of tolerability as the GLP-1/dual-agonist race moves deeper into late-stage programs.